Search research articles
Contact Us
Filters
Showing results (121-130 of 364) with videos related to
Page
of 37
Sort By:
Cancer Research
|
February 26, 2014
RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance
Yeong-In Yang, Ji-Hye Ahn, Kyung-Tae Lee, et al.
The American Journal of Pathology
|
August 30, 2005
Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor
Martin Köbel, Gudrun Pohl, Wolfgang D Schmitt, et al.
Fertility and Sterility
|
February 28, 2006
Expression of L-selectin ligands in human endometrium during the implantation window after controlled ovarian stimulation for oocyte donation
Tsung-Hsuan Lai, Yulian Zhao, Ie-Ming Shih, et al.
The American Journal of Pathology
|
April 12, 2002
Diverse tumorigenic pathways in ovarian serous carcinoma
Gad Singer, Robert J Kurman, Hsueh-Wei Chang, et al.
Frontiers in Immunology
|
November 24, 2025
Macrophages and neutrophils in ovarian cancer microenvironment
Kuang-Chao Cheng, Yu-Hsin Lin, Dao-Sian Wu, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
July 14, 2015
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study
Russell Vang, Douglas A Levine, Robert A Soslow, et al.
Molecular & Cellular Proteomics : MCP
|
November 23, 2012
Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery
Mark A Marzinke, Caitlin H Choi, Li Chen, et al.
Human Pathology
|
October 18, 2005
Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome
Chih-Yi Hsu, Robert J Kurman, Russell Vang, et al.
Cancer Research
|
March 9, 2005
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations
Gudrun Pohl, Chung-Liang Ho, Robert J Kurman, et al.
International Journal of Molecular Sciences
|
May 27, 2011
Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma
Daichi Maeda, Tsui-Lien Mao, Masashi Fukayama, et al.
Page
of 37
Search research articles
Search
Showing results (121-130 of 364) with videos related to
Sort By:
Page
of 37
Cancer Research
|
February 26, 2014
RSF1 is a positive regulator of NF-κB-induced gene expression required for ovarian cancer chemoresistance
Yeong-In Yang, Ji-Hye Ahn, Kyung-Tae Lee, et al.
The American Journal of Pathology
|
August 30, 2005
Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor
Martin Köbel, Gudrun Pohl, Wolfgang D Schmitt, et al.
Fertility and Sterility
|
February 28, 2006
Expression of L-selectin ligands in human endometrium during the implantation window after controlled ovarian stimulation for oocyte donation
Tsung-Hsuan Lai, Yulian Zhao, Ie-Ming Shih, et al.
The American Journal of Pathology
|
April 12, 2002
Diverse tumorigenic pathways in ovarian serous carcinoma
Gad Singer, Robert J Kurman, Hsueh-Wei Chang, et al.
Frontiers in Immunology
|
November 24, 2025
Macrophages and neutrophils in ovarian cancer microenvironment
Kuang-Chao Cheng, Yu-Hsin Lin, Dao-Sian Wu, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
July 14, 2015
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study
Russell Vang, Douglas A Levine, Robert A Soslow, et al.
Molecular & Cellular Proteomics : MCP
|
November 23, 2012
Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery
Mark A Marzinke, Caitlin H Choi, Li Chen, et al.
Human Pathology
|
October 18, 2005
Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome
Chih-Yi Hsu, Robert J Kurman, Russell Vang, et al.
Cancer Research
|
March 9, 2005
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations
Gudrun Pohl, Chung-Liang Ho, Robert J Kurman, et al.
International Journal of Molecular Sciences
|
May 27, 2011
Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma
Daichi Maeda, Tsui-Lien Mao, Masashi Fukayama, et al.
Page
of 37